Search Clinical Trials in the European Union

Duration
Visits
Confirmation phase (III)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
301-320 of 1,307 trials

Chronic Kidney Disease in Children: Finerenone Study

We are studying how well finerenone works and its safety for children with chronic kidney disease and proteinuria. This trial will help us understand its effects when used with standard treatments.

ProteinuriaChronic Kidney Disease6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNephrology

Chronic Kidney Disease: Finerenone Safety Study

We are studying the long-term safety of finerenone for children and young adults with chronic kidney disease. This trial looks at its effects when used alongside standard treatments like ACE inhibitors or ARBs.

Chronic Kidney DiseaseProteinuria1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNephrologyPediatrics

Dopaminergic Pathway Changes in Comatose Patients with Traumatic Brain Injury

We are studying how traumatic brain injuries affect dopamine pathways in patients who are in a coma. This research may help us understand recovery patterns and improve future treatments.

Traumatic Brain Injury>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboInvestigational MedicinesNeurologyOtolaryngology

Progressive Pulmonary Fibrosis: Inhaled Treprostinil Study

We are investigating whether inhaled treprostinil can improve lung function in people with progressive pulmonary fibrosis. The study will also assess its safety and impact on overall health.

Progressive Pulmonary Fibrosis1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesPulmonology

Non-Transfusion-Dependent Thalassemia: Luspatercept Treatment

We are studying whether luspatercept can improve brain oxygen levels and blood flow in patients with non-transfusion-dependent thalassemia. The trial also looks at its effects on cognitive function and heart health.

Non-transfusion Dependent Beta-Thalassemia6-12 monthsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesHematologyNeurology

Lung Cancer Treatment: MK-2870 vs. Chemotherapy

We are studying a new drug, MK-2870, for patients with advanced lung cancer who have already tried other treatments. The goal is to see if it works better than standard chemotherapy options.

Non-small Cell Lung Cancer>2 yearsConfirmation phase (III)Investigational MedicinesOncology

High Cardiovascular Risk: Rosuvastatin vs. Combination Therapy

We are studying whether high-intensity rosuvastatin or a combination of rosuvastatin and ezetimibe can effectively lower cholesterol in patients at high or very high risk for heart disease. The goal is to see if these treatments help achieve specific cholesterol targets.

High Cholesterol≤3 monthsConfirmation phase (III)Monitoring phase (IV)≤5 visitsNo PlaceboInvestigational MedicinesCardiologyInternal Medicine

Prostate Cancer Recurrence: PSMA PET/CT vs. Salvage Radiotherapy

We are comparing a personalized treatment approach using PSMA PET/CT imaging with standard salvage radiotherapy for patients whose prostate cancer has returned after surgery. The goal is to see which method better helps manage their condition and improves quality of life.

Recurrent Prostate Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteOncology

Breast Cancer: MK-2870 with or without Pembrolizumab

We are comparing a new treatment for advanced breast cancer that can't be surgically removed to standard chemotherapy. This study aims to see if the new treatment improves outcomes for patients.

Hormone Receptor Positive Breast Cancer>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesOncology

Non-Small Cell Lung Cancer: V940 and Pembrolizumab Study

We are testing a new treatment combining V940 with pembrolizumab for patients with resected stage II to IIIB non-small cell lung cancer. The study aims to see if this combination improves survival and quality of life compared to a placebo.

Non-small Cell Lung Cancer>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementOncology

Hysterectomy Pain Relief: Local Anesthetic Study

We are testing whether injecting a local anesthetic before a vaginal hysterectomy helps reduce pain during the procedure. This study is for women undergoing hysterectomy using the vNOTES approach.

Hysterectomy>2 yearsConfirmation phase (III)Gynecology and Obstetrics

Triple-Negative Breast Cancer: MK-2870 with Pembrolizumab

We are studying a new treatment combining MK-2870 and pembrolizumab for people with triple-negative breast cancer who had surgery but did not respond completely. The trial aims to see if this combination works better than standard treatment options.

Triple Negative Breast Cancer>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Cervical Cancer: Surgery Plus Therapy Study

We are investigating whether additional therapy after surgery helps patients with early-stage, intermediate-risk cervical cancer stay cancer-free. This study compares outcomes with and without further treatment.

Early-Stage Cervical Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteOncology

Surgical Site Infection Prevention: Linezolid vs. Vancomycin

We are studying whether linezolid is as effective as vancomycin in preventing infections after surgery. This trial includes various surgeries and looks at infection rates and patient experiences.

Surgical Antibiotic Prophylaxis>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteInfectious DiseasesOrthopedics and Traumatology

Advanced Breast Cancer: Capivasertib with CDK4/6 Inhibitors

We are studying a new treatment combining capivasertib with CDK4/6 inhibitors and fulvestrant for patients with advanced hormone receptor-positive, HER2-negative breast cancer. The goal is to see if this combination improves treatment outcomes compared to standard therapies.

Hormone Receptor-Positive and HER2-Negative Breast Cancer3-6 monthsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Acute Myeloid Leukemia: CHIP-AML22 Trial

We are studying new treatment options for children and adolescents with newly diagnosed AML to see if they improve survival and reduce side effects compared to standard therapies.

Acute Myeloid Leukemia6-12 monthsConfirmation phase (III)No PlaceboInvestigational MedicinesHematologyPediatrics

Colchicine for Heart Health After PCI

We are studying whether colchicine can help reduce serious heart events in patients with coronary artery disease after a heart procedure. This trial compares colchicine to a placebo to see its effects on heart health.

Coronary Artery DiseaseConfirmation phase (III)6-10 visitsStandard MedicinesCardiologyInternal Medicine

Long-Term Study of Delandistrogene Moxeparvovec (SRP-9001)

We are assessing the long-term safety and effectiveness of delandistrogene moxeparvovec in individuals who previously participated in a clinical study. This research aims to understand how the treatment continues to affect participants over time.

Duchenne Muscular Dystrophy>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementNeurologyOrthopedics and Traumatology

Advanced Non-Squamous NSCLC: Dato-DXd with Rilvegostomig

We are studying if a new treatment combination is safe and effective compared to pembrolizumab for patients with advanced non-squamous lung cancer. This trial is for those with high PD-L1 levels and no specific genetic changes.

Non-Small Cell Lung CancerConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Pulmonary Arterial Hypertension: Treprostinil Sodium for Kids

We are studying the safety and tolerability of a new preservative-free medication for children with pulmonary arterial hypertension. The trial also looks at how it may improve their quality of life and symptoms.

Pulmonary Arterial Hypertension3-6 monthsConfirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemotePediatricsPulmonology